Analysts expect Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) to announce earnings per share (EPS) of ($0.71) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Checkmate Pharmaceuticals’ earnings, with estimates ranging from ($0.71) to ($0.70). Checkmate Pharmaceuticals posted earnings per share of ($0.84) during the same quarter last year, which would indicate a positive year over year growth rate of 15.5%. The firm is expected to report its next quarterly earnings report on Friday, November 12th.
On average, analysts expect that Checkmate Pharmaceuticals will report full year earnings of ($2.95) per share for the current fiscal year, with EPS estimates ranging from ($3.00) to ($2.89). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.65) per share, with EPS estimates ranging from ($3.09) to ($2.20). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover Checkmate Pharmaceuticals.
Checkmate Pharmaceuticals (NASDAQ:CMPI) last issued its earnings results on Thursday, August 12th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.14).
Checkmate Pharmaceuticals stock traded up $0.04 during trading on Monday, hitting $4.07. 34 shares of the company were exchanged, compared to its average volume of 38,829. The business’s 50 day moving average is $4.87 and its 200 day moving average is $6.11. Checkmate Pharmaceuticals has a 52 week low of $3.63 and a 52 week high of $23.10. The company has a market capitalization of $88.03 million, a P/E ratio of -0.90 and a beta of 1.35.
Large investors have recently made changes to their positions in the business. Ergoteles LLC bought a new position in Checkmate Pharmaceuticals in the 2nd quarter valued at $158,000. Millennium Management LLC bought a new position in Checkmate Pharmaceuticals in the 2nd quarter valued at $241,000. Renaissance Technologies LLC bought a new position in Checkmate Pharmaceuticals in the 2nd quarter valued at $140,000. Alberta Investment Management Corp bought a new position in Checkmate Pharmaceuticals in the 2nd quarter valued at $149,000. Finally, Advisory Services Network LLC bought a new position in Checkmate Pharmaceuticals in the 2nd quarter valued at $46,000. Hedge funds and other institutional investors own 75.49% of the company’s stock.
Checkmate Pharmaceuticals Company Profile
Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naÃ¯ve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.
Read More: What is the price-sales ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.